This Popular ETF Just Had 1 of Its Biggest Portfolio Adjustments Ever. What Investors Need to Know.

Schwab U.S. Dividend Equity ETF's underlying index underwent a 31% March 2026 reconstitution, adding 25 stocks and removing 22, with energy exposure cut from 23.5% to 16.3%. Healthcare and technology weights rose to 18.9% and 11.2%, while major holdings were reshuffled, including the removal of AbbVie and Cisco and the addition of UnitedHealth, Abbott Labs, and Procter & Gamble. The change is a notable portfolio rotation but is unlikely to have broad market impact.

Analysis

The key second-order effect is that SCHD’s reconstitution is not just a style rebalance; it is a forced rotation out of the most crowded dividend-energy winners into sectors with more durable payout visibility. That matters because the index is effectively monetizing a momentum trade in energy and reallocating toward cash-flow compounding in healthcare, staples, and quality tech, which should reduce tracking error drag if oil chops lower over the next 3–6 months.

UNH and ABT look like the cleanest beneficiaries because they add dividend durability without requiring cyclical assumptions; both also improve the portfolio’s earnings-growth mix, which should help SCHD’s relative performance if rates stay range-bound and investors continue favoring defensive quality over pure yield. TXN’s rise is more interesting: it suggests the market is rewarding semi-cycle cash generation inside a dividend wrapper, and that could spill over to other high-FCF industrial/tech compounders that screen well on capital return but are not traditionally “dividend ETF” names.

The likely losers are the prior energy leaders, especially CVX and COP on a relative basis, because the ETF shift removes a source of incremental demand just as their stocks have benefited from a strong tape. That said, the move may be underdone if energy weakens further: the reweighting still leaves meaningful exposure, so SCHD is not fully de-risked from oil. The bigger risk to the new mix is a sharp rates rally, which would punish the higher-duration healthcare and staples names and could make the replacement basket look more expensive on a dividend-growth basis.

My base case is that the reconstitution lowers near-term upside from energy beta but improves drawdown characteristics into summer. If oil mean-reverts and defensives stay bid, the new composition should outperform the broad market on a risk-adjusted basis; if energy rips again, SCHD will lag, but the opportunity cost may be limited because the previous overweight had already captured much of the easy upside.

Key Decisions for Investors

• Overweight UNH and ABT versus CVX/COP for the next 1-2 quarters: the portfolio is shifting toward durable dividend growers, and these names should have better relative support if oil cools and the market stays defensive.
• Pair trade: long SCHD / short XLE for 3-6 months if crude remains volatile; the ETF has already trimmed its energy beta while still preserving quality income exposure, so this is a cleaner way to express a mean-reversion view on oil.
• Long TXN on pullbacks over the next month: the reconstitution validates demand for high-FCF tech inside dividend portfolios, and TXN has room to rerate if investors chase quality plus capital returns.
• Avoid chasing CVX and COP after the reweight unless oil breaks materially higher; the forced index selling removes a technical tailwind and raises the bar for incremental upside.
• If rates fall, add PG/KO as a defensive duration hedge against the new SCHD mix; if rates rise, consider trimming healthcare exposure first because the new basket is more rate-sensitive than the old energy-heavy one.